Objectives

Delivered by our CME division, PCM Scientific, the latest live webinar from HCM Academy ‘Integrating Cardiac Myosin Inhibitors into the Contemporary Management of HCM Patients’ delivered actionable strategies to enhance patient care.

The free educational live event, held in November 2024, aimed to enhance healthcare professionals’ understanding of cardiac myosin inhibitors and their role in managing hypertrophic cardiomyopathy (HCM). The key objectives were to:

  • Assess the pathogenic biology of HCM and sarcomeric dysfunction.
  • Explain the effects of cardiac myosin inhibitors on HCM patients.
  • Formulate treatment plans integrating these new treatments into current HCM management strategies.

Our approach

PCM Scientific worked closely with expert faculty to develop the educational agenda for the 60-minute live event. This expert-led webinar featured Dr. Martin Maron, Director of the HCM Center at Lahey Hospital, and a leading researcher in HCM and Professor Iacopo Olivotto, Chief of Cardiology at Meyer Children’s Hospital, and an authority on HCM management.

The session covered essential topics such as the role of the sarcomere in HCM, the mechanism of action of myosin inhibitors, available medications, patient suitability, and real-world data. It also included a live Q&A for direct engagement with the speakers.

The event was promoted to our audience of over 88,000 secondary healthcare professionals in the UK, USA, and Europe, via a variety of tactics, including emails, online advertising, newsletter advertising, social media, partnerships with the Hypertrophic Cardiomyopathy Association (HCMA) – all to drive registrations and awareness.

Outcome

  • 88,000+ secondary care HCP reach
  • 4,000+ views

The webinar attracted over 4,000 views to date, with a 4.8/5 rating for overall quality from attendees, and 100% of participants said the webinar met their educational needs and would recommend it to other healthcare providers.

The session will be available on-demand through the HCM Academy website, ensuring continued access for healthcare professionals.

This successful event underscores our commitment to providing high-quality, expert-led education to improve the management of HCM and enhance patient outcomes.

This independent educational activity is supported by funding from Bristol Myers Squibb and Cytokinetics. AffinityCE. is an ACCME accredited independent CME provider responsible for the provision of this independent CME Activity. PCM Scientific, working in partnership with AffinityCE is the medical education company acting as scientific secretariat and organizer for this program.

All activities are run at arm’s length from the financial supporters. No funder has had input into the content of the materials or presentations available.